CDT Equity QIMA Tapinarof Skin Partnership
Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The partnership is a small-cap biotech research collaboration with no near-term revenue, so its market impact is limited to Equity Group shares, which fell sharply in pre-market trading. Broader market effects are negligible, though it highlights continued interest in autoimmune dermatology assets and the contract research sector.
Equity Group (Nasdaq: CDT) announced on September 18, 2026 that it has entered into a partnership with QIMA Life Sciences, a French contract research organization specializing in preclinical dermatology, to explore several of CDT's assets in autoimmune skin diseases. The collaboration will leverage QIMA's access to human skin from healthy donors and patients, providing clinically relevant data intended to accelerate translation to the clinic and give potential license partners confidence. Initial studies will center on tapinarof, marketed as VTAMA, which is approved for plaque psoriasis and atopic dermatitis in the United States and Japan. CDT holds an intellectual property portfolio around tapinarof, including solid form and method-of-use patents in combination with other drugs, and QIMA will test these novel combinations in psoriatic patient skin with the goal of developing a second-generation tapinarof product with greater efficacy and patient benefit. CDT also plans to investigate its proprietary tapinarof combinations in vitiligo, a chronic autoimmune disorder affecting approximately 0.5% to 2.0% of the global population. The global vitiligo drug market was estimated at about $2.6 billion in 2025 and is projected to reach $6.6 billion by 2030. Despite the announcement, CDT shares fell in pre-market Nasdaq trading, reportedly down 9.23 percent to $0.1720 after closing the prior session 4.29 percent lower.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard